



Clinical Study Underway to Assess Non-Invasive Diabetes Monitoring with Saliva Analyzer Prototype

Diabetes Patients of Designated Hartford HealthCare Facilities Eligible to Participate

Privately owned biomedical technology company Quick LLC began sponsoring a clinical study this month comparing glucose analysis from the company's prototype *iQuickIt™ Saliva Analyzer* to corresponding venipuncture (blood draw) and finger stick glucose analyses. The *iQuickIt Saliva Analyzer* aims to provide a non-invasive daily solution for people with diabetes to check blood glucose levels using saliva in place of traditional finger stick blood tests.

In conjunction with Hartford HealthCare, the clinical study is currently underway at The Hospital of Central Connecticut New Britain General campus in the Emergency Department and in the Department of Endocrinology as well as in the Emergency Department of Hartford Hospital. Diabetes patients seeking medical treatment or with scheduled appointments at these locations can voluntarily elect to be part of the study if a blood glucose level is obtained as a part of their clinical evaluation. Plans are also underway to begin collecting saliva samples for the clinical study at Hospital of Central Connecticut's Center for Metabolic Health in Southington.

Participants in the study will provide clinical research assistants with a saliva sample when their blood glucose levels are checked by finger stick or blood draw. They are required to refrain from food, gum and non-water beverages for 10 minutes prior to providing a saliva sample. Summary results from the study will be available for participants to view on www.iQuickIt.com once statistical significance is achieved with data to compare approximately 1,000 saliva samples with 500 finger stick readings and 500 venipuncture samples.



Quick clinical research assistants in Hartford Hospital Emergency Department



iQuickIt Saliva Analyzer Prototype image

Seeking to revolutionize diabetes care, developers of the patent-pending *iQuickIt Saliva Analyzer* are physicians with extensive clinical experience and biotechnology development savvy.


“Our hope is to provide a simpler testing method that fosters more widespread, consistent patient testing and leads to better diabetes management for patients,” said William A. Petit Jr, MD, principal investigator of the study and diabetes advisor for Quick LLC. “In addition to removing barriers to testing, the



iQuickIt Saliva Analyzer aims to enable real-time test result sharing to smart devices for convenient monitoring by parents, care-givers and medical professionals.”

Renowned diabetes specialist William A. Petit Jr, MD previously served as Medical Director of the Joslin Diabetes Center and Director of Clinical Research at the Hospital of Central Connecticut, and had a clinical practice of Endocrinology, Diabetes, Metabolism and Internal Medicine. With an expansive career specialty researching and treating diabetes, Dr. Petit has served on various medical associations and been honored with numerous professional accolades in addition to writing multiple books and publishing more than a dozen scientific papers on related topics.

Participation in the study is anonymous and one-time only. Patients will not be contacted in the future and other medical providers do not have access to personal information provided for study purposes.



*Quick clinical research assistants in the
Hospital of Central Connecticut
New Britain General campus
Emergency Department*